Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36543789.
- Also identified by DOI 10.1038/s41467-022-35586-7 and PMC identifier 9772378.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Contemporary influenza A H3N2 viruses circulating since 2016 have acquired a glycosylation site in the neuraminidase in close proximity to the enzymatic active site. Here, we investigate if this S245N glycosylation site, as a result of antigenic evolution, can impact binding and function of human monoclonal antibodies that target the conserved active site. While we find that a reduction in the inhibitory ability of neuraminidase active site binders is measurable, this class of broadly reactive monoclonal antibodies maintains protective efficacy in vivo.
Medical subject headings
- Antibodies, Monoclonal
- Influenza A Virus, H3N2 Subtype
- Neuraminidase